UroGen Pharma Dirección

Dirección controles de criterios 2/4

El CEO de UroGen Pharma's es Liz Barrett , nombrado en Jan 2019, tiene una permanencia de 5.25 años. compensación anual total es $1.87M, compuesta por 40.9% salario y 59.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.96% de las acciones de la empresa, por valor de €4.33M. La antigüedad media del equipo directivo y de la junta directiva es de 3.9 años y 5.9 años, respectivamente.

Información clave

Liz Barrett

Chief Executive Officer (CEO)

US$4.6m

Compensación total

Porcentaje del salario del CEO	17.1%
Permanencia del CEO	5.3yrs
Participación del CEO	1.0%
Permanencia media de la dirección	4.2yrs
Promedio de permanencia en la Junta Directiva	6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Liz Barrett en comparación con los beneficios de UroGen Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$5m	US$794k	-US$102m
Sep 30 2023	n/a	n/a	-US$105m
Jun 30 2023	n/a	n/a	-US$109m
Mar 31 2023	n/a	n/a	-US$112m
Dec 31 2022	US$2m	US$764k	-US$110m
Sep 30 2022	n/a	n/a	-US$109m
Jun 30 2022	n/a	n/a	-US$114m
Mar 31 2022	n/a	n/a	-US$113m
Dec 31 2021	US$4m	US$739k	-US$111m
Sep 30 2021	n/a	n/a	-US$113m
Jun 30 2021	n/a	n/a	-US$111m
Mar 31 2021	n/a	n/a	-US$117m
Dec 31 2020	US$2m	US$637k	-US$128m
Sep 30 2020	n/a	n/a	-US$137m
Jun 30 2020	n/a	n/a	-US$130m
Mar 31 2020	n/a	n/a	-US$121m
Dec 31 2019	US$26m	US$695k	-US$105m

Compensación vs. Mercado: La compensación total de Liz($USD1.87M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.02M).

Compensación vs. Ingresos: La compensación de Liz ha aumentado mientras la empresa no es rentable.

CEO

Liz Barrett (61 yo)

5.3yrs

Permanencia

US$4,639,589

Compensación

Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She has been a Director at Allogene Therapeutics, Inc. sin...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Elizabeth Barrett	President	5.3yrs	US$4.64m	0.96% $ 4.1m
Jason Smith	General Counsel	3.8yrs	US$1.51m	0.069% $ 293.1k
Mark Schoenberg	Chief Medical Officer	6.4yrs	US$1.36m	0.54% $ 2.3m
Dong Kim	Chief Financial Officer	2.2yrs	US$738.02k	0.10% $ 441.3k
Vincent Perrone	Senior Director of Investor Relations	no data	sin datos	sin datos
Bryon Wornson	Executive Vice President of Talent	less than a year	sin datos	sin datos
Marina Konorty	Executive Vice President of Research & Development and Technical Operations	4.2yrs	sin datos	sin datos
Jeffrey Bova	Chief Commercial Officer	4.2yrs	sin datos	sin datos
James Ottinger	Executive Vice President of Regulatory Affairs & Quality	4.2yrs	sin datos	sin datos
Polly Murphy	Chief Business Officer	3.7yrs	sin datos	sin datos
Michael Louie	Senior Vice President of Medical Affairs & Clinical Development	less than a year	sin datos	sin datos
Gil Hakim	Consultant	5.8yrs	US$3.86m	sin datos

4.2yrs

Permanencia media

55.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de UR8 se considera experimentado (3.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Elizabeth Barrett	President	5.3yrs	US$4.64m	0.96% $ 4.1m
Fred Cohen	Independent Director	7yrs	US$193.76k	0.044% $ 187.8k
Cynthia Butitta	Independent Director	6.6yrs	US$204.06k	0% $ 0
Stuart Holden	Independent Director	8.4yrs	US$201.53k	0% $ 0
Arie Belldegrun	Independent Chairman	11.4yrs	US$342.18k	1.2% $ 5.1m
Daniel Wildman	Independent Director	1.5yrs	US$192.72k	0% $ 0
Jack Baniel	Member of Scientific Advisory Board	no data	sin datos	sin datos
Herbert Lepor	Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Fred Witjes	Member of Scientific Advisory Board	no data	sin datos	sin datos
James Robinson	Independent Director	less than a year	US$313.29k	0.000010% $ 42.7
Leana Wen	Independent Director	1.8yrs	US$194.41k	0% $ 0

6.0yrs

Permanencia media

66.5yo

Promedio de edad

Junta con experiencia: La junta directiva de UR8 se considera experimentada (5.9 años de antigüedad promedio).

UroGen Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Chief Medical Officer recently sold €155k worth of stock

General Counsel recently sold €73k worth of stock

UroGen Pharma Ltd. Announces the Appointment of James Robinson to Its Board of Directors

Urogen Pharma Ltd. Appoints Dan Wildman to the Board of Directors

Urogen Pharma Ltd. Appoints Dr. Leana S. Wen to the Board of Directors and Audit Committee

UroGen Pharma Ltd., Annual General Meeting, Jun 08, 2022

Recent updates

UroGen Pharma Ltd. Reports on New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy

UroGen Pharma Ltd. to Report Q1, 2024 Results on May 13, 2024

Chief Medical Officer recently sold €155k worth of stock

Full year 2023 earnings released: US$3.55 loss per share (vs US$4.81 loss in FY 2022)

UroGen Pharma Ltd. to Report Q4, 2023 Results on Mar 14, 2024

General Counsel recently sold €73k worth of stock

UroGen Pharma Ltd. Initiates Submission of a Rolling NDA to the FDA for UGN-102

UroGen Pharma Ltd. Plans to Initiate Phase 3 Study in 2024

Forecast to breakeven in 2026

Forecast to breakeven in 2025

UroGen Pharma Ltd. Reiterates Revenue Guidance for the Full Year 2023

UroGen Pharma Ltd. to Report Q3, 2023 Results on Nov 14, 2023

UroGen Pharma Ltd. Reiterates Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$1.03 loss per share (vs US$1.18 loss in 2Q 2022)

UroGen Pharma Ltd. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Shareholder dilution

Forecast to breakeven in 2025

UroGen Pharma Ltd. Announces Positive Topline Data From its Phase 3 Trials ATLAS and ENVISION studying UGN-102

UroGen Pharma Ltd. Announces the Appointment of James Robinson to Its Board of Directors

UroGen Pharma Ltd. Announces Retrospective Study Finds Jelmyto Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors That Impede Kidney Preservation

First quarter 2023 earnings released: US$1.30 loss per share (vs US$1.26 loss in 1Q 2022)

UroGen Pharma Ltd. Reiterates Earnings Guidance for the Full Year 2023

UroGen Pharma Ltd. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$4.79 loss per share (vs US$4.96 loss in FY 2021)

No longer forecast to breakeven

UroGen Pharma Ltd. Announces Preliminary Results of Study to Assess the Feasibility of Home Instillation of UGN-102 (Mitomycin) for Intravesical Solution

UroGen Pharma Ltd. Highlights Results from the First and Largest Post-Commercial Utilization Review of JELMYTO for Pyelocalyceal Solution

Forecast to breakeven in 2025

UroGen Pharma Ltd. Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer

Urogen Announces New Data from the Optima II Study That Show Median Durability of Response of 24.4 Months for UGN-102

UroGen Pharma Ltd. Announces New Data from the Olympus Trial That Shows Median Durability of Response of 28.9 Months for JELMYTO

Third quarter 2022 earnings released: US$1.13 loss per share (vs US$1.35 loss in 3Q 2021)

UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma

Third quarter 2022 earnings released: US$1.13 loss per share (vs US$1.35 loss in 3Q 2021)

Urogen Pharma Ltd. Appoints Dan Wildman to the Board of Directors

UroGen Pharma Ltd. to Report Q3, 2022 Results on Nov 10, 2022

FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following Reconstitution

Urogen Pharma Ltd. Appoints Dr. Leana S. Wen to the Board of Directors and Audit Committee

Second quarter 2022 earnings released: US$1.18 loss per share (vs US$1.17 loss in 2Q 2021)

UroGen Pharma Ltd. to Report Q2, 2022 Results on Aug 11, 2022

UroGen Pharma Ltd.(NasdaqGM:URGN) dropped from Russell 2000 Dynamic Index

UroGen Pharma Ltd. Provides Revenue Guidance for the Full Year 2022

UroGen Pharma Ltd. to Report Q1, 2022 Results on May 10, 2022

UroGen Pharma Ltd., Annual General Meeting, Jun 08, 2022

Insufficient new directors

UroGen Pharma Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (Zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer

UroGen Pharma Ltd. announced that it expects to receive $100 million in funding from Pharmakon Advisors, LP

UroGen Pharma Ltd. to Report Q4, 2021 Results on Mar 10, 2022

Urogen Pharma Ltd. Submits Investigational New Drug Application Supporting Planned Phase 1 Clinical Study of Ugn-301 Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer

UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients

UroGen Pharma Ltd Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma Ltd. Doses First Patient in Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

Third quarter 2021 earnings released: US$1.35 loss per share (vs US$1.31 loss in 3Q 2020)

UroGen Pharma Ltd. Announces Final Data from Two Key Trials, Evaluating the Safety and Efficacy of Investigational Agent UGN-102

Insufficient new directors

Full year 2020 earnings released: US$5.90 loss per share (vs US$5.12 loss in FY 2019)

UroGen Pharma Ltd. Announces Sponsored Research Agreement with the Johns Hopkins University School of Medicine to Expand Immuno-Oncology Pipeline

UroGen Pharma Ltd. to Report Q4, 2020 Results on Mar 18, 2021

New 90-day high: €21.60

UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer

New 90-day low: €14.20

President recently bought €152k worth of stock

New 90-day low: €15.10

Urogen Pharma Ltd. Announces Final Data from the UGN-101 Jelmyto® (mitomycin) for Pyelocalyceal Solution Phase 3 Olympus Trial in Patients with Low-Grade Upper Tract Urothelial Cancer

UroGen Announces Final Results from the Single-Arm, Open-Label Optima II Phase 2B Trial Evaluating the Efficacy and Safety of Investigational UGN-102

Centers for Medicare & Medicaid Services Issues Permanent J-Code for Urogen’S Jelmyto® Effective January 1, 2021

Revenue beats expectations

UroGen Pharma Ltd. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low: €16.20